Clinical Trials Logo

Vaginal Dryness clinical trials

View clinical trials related to Vaginal Dryness.

Filter by:

NCT ID: NCT06282614 Not yet recruiting - Vaginal Dryness Clinical Trials

Performance and Safety of MUCOGYNE® Ovule as a Moisturizer

MOVHYDA
Start date: March 2024
Phase: N/A
Study type: Interventional

The aim of this post-Market Clinical Follow-up (PMCF) study is to confirm the efficacy and safety of MUCOGYNE® Ovule in the maintainance of natural moisture of the vulvovaginal mucosa and in the compensation for any natural secretions deficiencies, when used in accordance with its approved labeling, in the context of vulvovaginal dryness.

NCT ID: NCT05913479 Recruiting - Vaginal Dryness Clinical Trials

Evaluation of the Efficacy and Safety of Mucogye® Gel as a Moisturizer

HYDRAGYNE
Start date: October 10, 2023
Phase: N/A
Study type: Interventional

The aim of this post-Market Clinical Follow-up (PMCF) study for a class IIb medical device is to confirm th efficacy and safety of Mucogyne Gel as a moisturizer in women with vaginal dryness irrespective of the cause; when used in accordance with its approved labelling.

NCT ID: NCT05644444 Completed - Dyspareunia Clinical Trials

Effectiveness and Safety of a Water-based and a Silicone-based Personal Lubricants With Sensory Action

Start date: February 20, 2023
Phase: N/A
Study type: Interventional

This clinical investigation will look at the effectiveness and safety of two personal lubricants for the relief of intimate discomfort associated with vaginal dryness.

NCT ID: NCT05156502 Not yet recruiting - Pain Clinical Trials

To Assess Signs and Symptoms in Women Affected by GSM After One Cycle of Pixel CO2-Alma Fractionated Laser

Start date: January 30, 2022
Phase: N/A
Study type: Interventional

Genitourinary syndrome of menopause (GSM) occurs in approximately 50% of menopausal women but is both underrecognized and undertreated despite numerous treatment options. Vaginal dryness, irritation, dyspareunia, urinary frequency, and urinary urgency are some of the more common symptoms that can have a negative effect on women's lives and relationships. In particular, dyspareunia is localized in the vestibule with specific trophic changes more evident than those localized in vagina. The CO2 fractionated laser, has also been found to be useful in several studies for the treatment of vaginal atrophy. In this open comparative study, 70 female menopausal subjects aged between 40 and 70 years old at inclusion, having symptoms of GSM (Vaginal dryness, burning/pain, dyspareunia,dysuria), have given her informed consent and meet all the eligibility criteria, will be enrolled. The two groups of comparison will be 35 subjects treated into vagina and vestibule, versus 35 subjects treated into vagina, only. Subjects will come to a total of 6 visits over a period of 3 months. The primary objective of the study is to evaluate the performance and safety of Pixel CO2-Alma Fractionated Laser comparing its administration into vagina and vestibule versus into vagina, only. The evaluated outcomes are vaginal dryness, burning/pain, dyspareunia, sensitivity to touch at Swab test, Female Sexual Function Index (FSFI) and Vulval Pain Functional Questionnaire (VQ) at day 84 and 120 and the safety during all the study. The secondary objectives are the evaluation of vaginal and vestibular trophism, measured by Vaginal Health Index (VHI) and Vestibular Health Score (VHS) at the FU visits.

NCT ID: NCT04908124 Completed - Dyspareunia Clinical Trials

A Clinical Investigation Into the Effectiveness and Safety of Five Water Based Personal Lubricants.

Start date: March 1, 2021
Phase: Phase 3
Study type: Interventional

This clinical investigation will look at the safety of five water based personal lubricants, and teir effectiveness the relief of intimate discomfort associated with vaginal dryness.

NCT ID: NCT04342559 Completed - Vaginal Dryness Clinical Trials

Acceptability, Under Use in Real Conditions Of Two Vaginal Moistures Indicated for Women With Vaginal Drying

PRV01
Start date: April 6, 2020
Phase: N/A
Study type: Interventional

The studies carried out to evaluate the safety and efficacy of products aimed at the intimate area of women aim to confirm the absence of risk associated with its use, identify possible feelings of discomfort and / or clinical signs resulting from the use of the product and evaluate the benefits provided by the use of the product such as, gynecologically tested, clinically tested, hydration for 72 hours, hydration, does not drip or drip little, feeling of natural hydration, control of natural vaginal odor, preserves vaginal pH, does not promote irritation, use vaginal topic, feeling of comfort, relief from dryness, easy use of the applicator, the applicator does not cause discomfort during application, preferably use at night, does not change the vaginal flora, reduces pain and discomfort during or shortly after sexual intercourse, does not promote discomfort during or shortly after intercourse, reduction of vaginal bleeding during or right after sexual intercourse, if there is a small amount left in the applicator, the treatment is not compromised. The research will be carried out with two new products for use in the internal intimate region in up to 74 research participants (up to 37 participants per product - each group of 37 will use one of the products), which meet the required inclusion and exclusion criteria. At the end of the treatment, the analysis must contain a minimum number of 30 participants per product. Participants will use the test products for 22 (+ 2) days and will be evaluated and monitored throughout the study by a gynecologist to verify the effectiveness of the products and possible adverse events. In addition, a profile questionnaire will be applied at the beginning of the study (T0 - day 1) and at the end of the study, the perceived efficacy questionnaire (T22), to assess signs and symptoms of the efficacy and safety of the product used.

NCT ID: NCT03782961 Not yet recruiting - Vaginal Dryness Clinical Trials

Evaluation of Viscosity of a Vaginal Moisturizer

Start date: January 14, 2019
Phase: Phase 4
Study type: Interventional

To evaluate the perception of viscosity of a vaginal moisturizer in postmenopausal women

NCT ID: NCT03714581 Recruiting - Dyspareunia Clinical Trials

Laser Therapy Following Radiotherapy for Gynecological Cancer

Start date: November 15, 2018
Phase: N/A
Study type: Interventional

Women with a history of pelvic radiotherapy due to gynecological cancer, will receive laser therapy for the management of genitourinary syndrome of menopause.

NCT ID: NCT03666819 Withdrawn - Clinical trials for Anatomic Stage III Breast Cancer AJCC v8

Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy

Start date: September 10, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well carbon dioxide fractional (CO2RE) laser works in treating participants with stage 0-III hormone receptor-positive breast cancer with vulvovaginal atrophy associated with dryness, inflammation or thinning of the epithelial lining of the vulva and vagina. CO2RE laser is a device that delivers controlled CO2 energy to the vaginal tissue and may help treat vaginal symptoms such as itching, burning, painful sexual intercourse, thickened or thin skin of the vulva, and stinging.

NCT ID: NCT03372720 Completed - Ovarian Carcinoma Clinical Trials

Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors

Start date: May 11, 2018
Phase: N/A
Study type: Interventional

This randomized pilot trial studies how well fractional carbon dioxide (CO2) laser therapy works in minimizing genitourinary syndrome of menopause (GSM) in gynecological cancer survivors. Fractional CO2 laser therapy may reduce symptoms of GSM in survivors of gynecologic cancers.